Metabolic Comorbidities and Risk of Development and Severity of Drug-Induced Liver Injury.

The objective of this review is to present the evidence for DILI and hepatotoxicity mechanisms, incidence, and outcomes in patients with MetS and nonalcoholic fatty liver disease. Moreover, we also summarize the relationships between drugs used to treat metabolic comorbidities and DILI. PMID: 31531370 [PubMed - in process]

https://www.ncbi.nlm.nih.gov/pubmed/31531370?dopt=Abstract

Source: Biomed Res - September 19, 2019 Category: Research Authors: Li X, Gao P, Niu J Tags: Biomed Res Int Source Type: research